The global arteriovenous fistula treatment market is projected to amass revenue of about US$ 1,356.5 million by 2033. The overall market value is expected to be worth US$ 765.8 million in 2023. The worldwide adoption of arteriovenous fistula treatment is projected to advance at a CAGR of 5.9% during this forecast period.
In the near future, the market for arteriovenous fistulas is also likely to be boosted by medicines in the clinical pipeline and supportive government efforts. However, risks associated with arteriovenous fistula needles are likely to create a dent in the market share growth.
The clearance given by FDI of Vascugel, an investigational novel medication for the treatment of failed hemodialysis access grafts, for a pivotal phase III trial by Pervasis Therapeutics, Inc. is one such instance. Therefore, these government initiatives and approvals are expected to open up a wide array of arteriovenous fistula treatment market opportunities and a sound foundation for the expansion of this market.
Due to ongoing efforts by leading companies to provide cutting-edge therapies for the treatment of arteriovenous fistula, the market size is expanding rapidly on a global scale. For instance, in April 2013, Shire released the results of a phase II research to determine the effectiveness and safety of SRM003 (Vascugel) in patients with end-stage renal disease and an arteriovenous fistula.
As per the market report by FMI, the arteriovenous fistula treatment methods are in research to come up in the market, and the same is also likely to sway the market.
For doctors to pinpoint the precise size and location of damaged blood arteries, imaging techniques like computed tomography (CT) and magnetic resonance imaging (MRI) are helpful, catering to the arteriovenous fistula treatment market growth. To effectively treat arteriovenous fistulas, additional surgical procedures are carried out. To reduce blood clotting in the affected locations, as fistulas in the brain and eye are tough to cure, injectable treatment is employed in this instance.
| Report Attributes or Data Points | Details |
|---|---|
| Global Arteriovenous Fistula Treatment Market Valuation in 2022 | US$ 731.6 million |
| Estimated Global Market Share in 2023 | US$ 765.8 million |
| Forecasted Global Market Size by 2033 | US$ 1,356.5 million |
| Projected Global Market Growth Rate from 2023 to 2033 | 5.9% CAGR |
| Historical Market Growth Rate from 2018 to 2022 | 3.8% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The adoption of arteriovenous fistula treatment is growing over the forecast period as the players are coming up with new treatment methods, such as photodynamic therapy, antiangiogenic therapy, and another method of sclerotherapy.
The effective treatment method for a complete cure in an easy way is still under development process, which initiates the players to come up with innovations for the treatment, shaping the market trends.
On the flip side, the lack of awareness regarding arteriovenous fistula treatment hinders the demand for arteriovenous fistula treatment worldwide.
The market for arteriovenous fistula treatment bears a huge potential as the treatment methods are limited, and the population effect is high, directly influencing the market growth.
| Regional Market Comparison | Global Market Share in Percentage |
|---|---|
| North America | 37.2% |
| Europe | 27.4% |
Due to the successful measures taken by the US government to create novel therapies for the arteriovenous fistula problem, North America controls the majority of the global market share, accounting for 37.2% in 2022.
To this, North America has a huge potential as leading pharmaceutical players are placed in that region, positively impacting the overall market over the forecast period.
| Regional Market Comparison | Global Market Share in Percentage |
|---|---|
| United States | 33% |
| Germany | 6.5% |
| Japan | 3.9% |
Principal Consultant
The second-leading market for arteriovenous fistulas is anticipated to be in Europe, with a share of 27.4% in 2022. Arteriovenous fistula incidence is rising, and there is a strong need for medicines to treat them in Europe, which is mostly responsible for the market's expansion in the region during the forecast period.
Europe's market growth has been soaring, attributed to rising awareness of the treatment in the region.
| Regional Markets | CAGR (2023 to 2033) |
|---|---|
| United Kingdom | 5.4% |
| China | 9.4% |
| India | 7.7% |
| Australia | 6.8% |
Numerous start-ups have been emerging in various industries, including the arteriovenous fistula treatment solutions, and are bringing about emerging trends in the market.
Example:
To raise the marketing of its FDA-cleared implant that enables patients with end-stage renal disease (ESRD) to more easily access their vascular system for hemodialysis, Vital Access, a start-up, obtained a US$10 million credit line from Deerfield Management.
The FDA approved the Salt Lake City, Utah-based company's device in 2013.
In 96% of patients with fistulas confirmed to be uncalculatable in the SAVE research, a prospective, pivotal clinical trial in the United States, it was demonstrated that VWING provided dependable fistula access.
In comparison to published rates, its usage in the study was linked to a significantly decreased incidence of access site and systemic infection over the long term.
| Category | By Type |
|---|---|
| Top Segment | Arteriovenous Fistulas |
| Market Share in Percentage | 29.8% |
| Category | By Treatment |
|---|---|
| Top Segment | Transcatheter Embolization |
| Market Share in Percentage | 42.7% |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Players in the market are engaging in various organic and inorganic strategies, including mergers & acquisitions, partnerships, product launches, and collaborations, thereby augmenting their market share.
Recent development:
The WavelinQTM 4F EndoAVF System, BD's next-generation technology, provides additional places to establish an AV fistula while leaving open the possibility of creating AV fistulas through regular surgical procedures in the future.
The surgical scar frequently left behind after creating an AV fistula during open surgery is removed with the endovascular technique, carried out through two tiny punctures or incisions.
Patients concerned about AV fistula formation with standard surgery may opt for an endoAVF.
Other Market Participants:
| Report Attributes | Details |
|---|---|
| Growth Rate | CAGR of 5.9% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
| Customization | Available Upon Request |
The projected revenue of the market by 2033 is US$ 1,356.5 million.
The market CAGR for 2033 is projected to be 5.9%.
North America, Europe, and Asia-Pacific are the leading market.
North America holds the largest market share.
North America is growing fast due to the rising prevalence of chronic diseases.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033
5.3.1. Arteriovenous Fistulas
5.3.2. Dural
5.3.3. Peripheral
5.3.4. Pial or Cerebral
5.3.5. Others
5.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Treatment Type, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Type, 2023 to 2033
6.3.1. Drugs
6.3.2. Transcatheter Embolization
6.3.3. Ultrasound-guided Compression
6.3.4. Surgery
6.4. Y-o-Y Growth Trend Analysis By Treatment Type, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Treatment Type, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Western Europe
7.3.4. Eastern Europe
7.3.5. South Asia and Pacific
7.3.6. East Asia
7.3.7. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. USA.
8.2.1.2. Canada
8.2.2. By Type
8.2.3. By Treatment Type
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Type
8.3.3. By Treatment Type
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Type
9.2.3. By Treatment Type
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Type
9.3.3. By Treatment Type
9.4. Key Takeaways
10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. United Kingdom.
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Western Europe
10.2.2. By Type
10.2.3. By Treatment Type
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Type
10.3.3. By Treatment Type
10.4. Key Takeaways
11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Poland
11.2.1.2. Russia
11.2.1.3. Czech Republic
11.2.1.4. Romania
11.2.1.5. Rest of Eastern Europe
11.2.2. By Type
11.2.3. By Treatment Type
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Type
11.3.3. By Treatment Type
11.4. Key Takeaways
12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Bangladesh
12.2.1.3. Australia
12.2.1.4. New Zealand
12.2.1.5. Rest of South Asia and Pacific
12.2.2. By Type
12.2.3. By Treatment Type
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Type
12.3.3. By Treatment Type
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Type
13.2.3. By Treatment Type
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Type
13.3.3. By Treatment Type
13.4. Key Takeaways
14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Type
14.2.3. By Treatment Type
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Type
14.3.3. By Treatment Type
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. USA.
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Type
15.1.2.2. By Treatment Type
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Type
15.2.2.2. By Treatment Type
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Type
15.3.2.2. By Treatment Type
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Type
15.4.2.2. By Treatment Type
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Type
15.5.2.2. By Treatment Type
15.6. United Kingdom.
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Type
15.6.2.2. By Treatment Type
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Type
15.7.2.2. By Treatment Type
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Type
15.8.2.2. By Treatment Type
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Type
15.9.2.2. By Treatment Type
15.10. Poland
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Type
15.10.2.2. By Treatment Type
15.11. Russia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Type
15.11.2.2. By Treatment Type
15.12. Czech Republic
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Type
15.12.2.2. By Treatment Type
15.13. Romania
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Type
15.13.2.2. By Treatment Type
15.14. India
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Type
15.14.2.2. By Treatment Type
15.15. Bangladesh
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Type
15.15.2.2. By Treatment Type
15.16. Australia
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Type
15.16.2.2. By Treatment Type
15.17. New Zealand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Type
15.17.2.2. By Treatment Type
15.18. China
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Type
15.18.2.2. By Treatment Type
15.19. Japan
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Type
15.19.2.2. By Treatment Type
15.20. South Korea
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Type
15.20.2.2. By Treatment Type
15.21. GCC Countries
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Type
15.21.2.2. By Treatment Type
15.22. South Africa
15.22.1. Pricing Analysis
15.22.2. Market Share Analysis, 2022
15.22.2.1. By Type
15.22.2.2. By Treatment Type
15.23. Israel
15.23.1. Pricing Analysis
15.23.2. Market Share Analysis, 2022
15.23.2.1. By Type
15.23.2.2. By Treatment Type
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Type
16.3.3. By Treatment Type
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Becton Dickinson & Company
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Medtronic
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. B. Braun Melsungen Ag
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Cook Medical
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Teleflex Incorporated
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Fresenius Medical Care AG & Co. KGaA
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. NxStage Medical Inc.
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Poly Medicure Limited.
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Shire plc
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Mayo Clinic
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.11. Proteon Therapeutics
17.1.11.1. Overview
17.1.11.2. Product Portfolio
17.1.11.3. Profitability by Market Segments
17.1.11.4. Sales Footprint
17.1.11.5. Strategy Overview
17.1.11.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Arteriovenous Fistula Treatment Market
